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Abstract
Background: Human prion diseases are relentlessly progressive neurodegenerative disorders which include sporadic
Creutzfeldt-Jakob disease (sCJD) and variant CJD (vCJD). Aside from variants of the prion protein gene (PRNP) replicated
association at genome-wide levels of significance has proven elusive. A recent association study identified variants in or
near to the PLCXD3 gene locus as strong disease risk factors in multiple human prion diseases. This study claimed the
first non-PRNP locus to be highly significantly associated with prion disease in genomic studies.
Methods: A sub-study of a genome-wide association study with imputation aiming to replicate the finding at PLCXD3
including 129 vCJD and 2500 sCJD samples. Whole exome sequencing to identify rare coding variants of PLCXD3.
Results: Imputation of relevant polymorphisms was accurate based on wet genotyping of a sample. We found no
supportive evidence that PLCXD3 variants are associated with disease.
Conclusion: The marked discordance in vCJD genotype frequencies between studies, despite extensive overlap
in vCJD cases, and the finding of Hardy-Weinberg disequilibrium in the original study, suggests possible reasons
for the discrepancies between studies.
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Background
Prion diseases are transmissible and fatal neurodegener-
ative disorders, affecting both humans and animals [1].
The human prion diseases comprise Creutzfeldt-Jakob
disease (CJD), kuru, proteinase sensitive prionopathy,
Gerstmann-Sträussler-Scheinker disease (GSS), fatal fa-
milial insomnia, and PrP Systemic Amyloidosis. 10–15 %
of all human prion disease is inherited as a germline
trait, caused by coding mutation of PRNP. Based on re-
cent GWAS, the major common genetic determinant of
sporadic or acquired prion disease risk is a missense
polymorphism at codon 129 of PRNP, encoding for the
cellular form of the prion protein, PrPc [2].
Recently a re-analysis of a previously published GWAS
[3] consisting of 85 vCJD cases and 1481 control
individuals found that after PRNP, the region most sig-
nificantly associated with disease was at the PLCXD3
gene locus. Resequencing three intronic SNPs near the
splice junction of intron 1 and exon 2 of this gene in
109 sCJD and 120 vCJD cases revealed that two of
these SNPs showed marked Hardy-Weinberg disequi-
librium and were highly significantly associated with
disease compared to publicly available controls [4]. As
this effect was extremely strong, we sought to replicate
the finding in a further cohort of human prion disease
cases to find out whether this gene was associated with
increased disease risk and investigate any effects on
clinical phenotype.
Methods
Summary and samples
We conducted a gene-specific study as a component of
GWAS with imputation comprising 2500 sCJD cases, 129
vCJD cases and 10,548 control individuals using established
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methods for quality control and statistical analysis (see
below). Patients with a diagnosis of sporadic CJD, of UK or
Northern European residence, were recruited by the Na-
tional Prion Clinic (NPC), London, the National CJD Re-
search and Surveillance Unit, Edinburgh and other
referrers in the UK in the period from 1995 to 2012. In the
UK 60 % had pathologically confirmed sCJD, the remainder
had a diagnosis of probable sCJD according to the pub-
lished WHO criteria with a high specificity (http://
www.cjd.ed.ac.uk/documents/criteria.pdf). Median age of
disease onset was 65 years. In Germany and USA, all cases
were pathologically confirmed. Probable or definite variant
CJD patients were diagnosed according to established cri-
teria (http://www.cjd.ed.ac.uk/documents/criteria.pdf). Due
to the very small number of vCJD patients in the UK
and worldwide (http://www.who.int/mediacentre/fact-
sheets/fs180), and because of an effective system of
sample sharing between Units in the UK, we can be
confident that the vCJD cases in our study included
the vast majority if not all 85 cases in the Bishop et al.
study. Mean age of onset of disease in this cohort of
patients was 30 years.
We calculated p-values of association for all SNPs located
within PLCXD3 and within 50 kilobases of the gene, includ-
ing for the three SNPs sequenced in the previous study,
rs545358, rs319013 and rs76547469, the former two of
which were reported as having allele and genotype frequen-
cies significantly different to publicly available European
control populations [4] using SNPTESTv2.5β [5]. As geno-
type data in our GWAS was imputed we confirmed that
imputation was accurate with both allele discrimination
PCR probes and Sanger sequencing. To further ascertain
mutations in PLCXD3 we reviewed next generation whole
exome sequencing data from 249 sCJD cases, 98 vCJD
cases, 29 iatrogenic CJD cases and 665 non-prion neu-
rodegenerative disease control individuals to identify
non-synonymous variants in the gene (see below).
Genome wide association study
Seven-hundred and thirty three UK sCJD cases, 818 Ger-
man sCJD cases, 951 US sCJD cases, 129 vCJD cases,
5020 UK Wellcome Trust Case—control Consortium con-
trol individuals, 2691 German KORA control individuals
and 2837 US control individuals were included. Samples
were genotyped on Illumina 550 K, 660 K, Illumina Hu-
man 1.2 M-Duo Custom (for WTCCC2 controls)
OmniExpress, Omni2.5 M or Omni5M arrays [6]. Prior to
imputation, samples were excluded if they had less than a
98 % call rate. SNPs were excluded with a missingness
greater than 1 %, minor allele frequency less than 1 % and
Hardy—Weinberg disequilibrium in controls <1 × 10−3.
Phasing and subsequent imputation were performed using
SHAPEITv2 and Imputev2.3.0 employing the 1000 Ge-
nomes Phase 1 integrated variant set [7]. SNPTESTv2.5β
was used for statistical association testing. This was per-
formed using the frequentist score method, which takes
genotype uncertainty into account, whilst applying an
additive genetic model. Four population covariates from a
principle components analysis (using PLINK multidimen-
sional scaling function) were included (resulting in
lambda = 1.06). Uncorrected P values are shown.
All samples were provided with informed consent for
research genetic studies with approval of local research
ethics committees. The study was approved by the
London Harrow Research Ethics Committee.
Confirmation of imputed genotypes with allele
discrimination probes and Sanger sequencing
Allele specific probes and primers were used to confirm
imputed genotypes at rs545358 and rs319013 in 176
sCJD and 119 vCJD cases. Sanger sequencing was used
to further confirm genotypes across these SNPs for 46
sCJD and 47 vCJD cases. For PCR amplification the for-
ward primer 5’-cacccataaggaaagccaat-3’and the reverse
primer 5’-gggtctctgggcttggt-3’ were used and for sequen-
cing the reverse primer reported in the previous study,
5’-catttccgcatgagcttttt-3’, was used [4].
Whole exome sequencing
Two-hundred and forty nine sCJD exomes, 98 vCJD
exomes, 29 iatrogenic CJD exomes and 665 control
exomes (consisting of Alzheimer’s disease, frontotem-
poral dementia, Huntington’s disease phenocopy and
glaucoma cases) were captured with SureSelect [8] and
HaloPlex [9] (Agilent) kits. Exomes were sequenced on
the Illumina HiSeq2000 platform with 100 bp paired-
end runs. Sequences were aligned to the human refer-
ence genome using Novoalign software [10]. The Gen-
ome Analysis Toolkit (GATK) Unified Genotyper [11, 12]
was used for SNP and indel calling then sequences were
recalibrated with the GATK Variant Recalibrator [13] and
variants annotated with ANNOVAR [14]. Variants were
annotated for location, function, including whether they
led to splice site changes, frameshift or stop codon muta-
tions, for SIFT (sorting intolerant from tolerant) [15] and
POLYPHEN (polymorphism phenotyping) [16] values,
which predict the functional effect of a variant, and for
whether they were novel, rare or somewhat rare based
upon frequency in the control dataset of 0 %, <0.2 % and
<0.5 % respectively. Variants were filtered out from the
analysis if they were synonymous, read depth was <8, the
variant had not been sequenced in >30 % of samples or
minor allele frequencies of the variant in control popula-
tions from Exome Variant Server (http://evs.gs.washingto-
n.edu/EVS) and/or 1000 Genomes (http://
www.ncbi.nlm.nih.gov/variation/tools/1000genomes/) was
>10 %. For heterozygous calls a minimum of 18 % of reads
were non-reference.
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For statistical analysis, allelic Fisher’s Exact tests were
performed for single variants associated with disease in
cases compared to controls. In addition gene based tests
were performed using a binomial probability test looking
at all non-synonymous variants within a gene in cases
compared to controls. Statistical analyses were performed
using R statistical package version 3.0.2.
In particular we also looked for novel variants not
found in any control populations. The control popula-
tions we referred to were the Wellcome Trust Case—-
control Consortium controls (www.wtccc.org.uk), the
Exome Variant Server, 1000 Genomes and Complete
Genomics 69 (http://www.completegenomics.com/pub-
lic-data/69-Genomes/) cohorts.
Results
Whilst we found modest evidence of association at SNPs
in the vicinity of exon 1 in vCJD, this was far from
genome-wide thresholds of significance in our sample,
which largely overlaps the samples used in the original
study (Fig. 1b) and therefore is not evidence of replication.
Elsewhere, and importantly at the splice junction of intron
1/exon 2, we found no Hardy-Weinberg disequilibrium or
association with disease for any SNPs in the GWAS data
consisting of 2500 sCJD cases, 129 vCJD cases and 10,548
control individuals (Fig. 1a and b). The PLCXD3 SNPs re-
ported to be associated with disease risk in the GWAS by
Bishop et al. [4] and the intronic SNPs found to have sig-
nificantly different allele and genotype frequencies be-
tween cases and publicly available controls showed no
association with disease in our study (Table 1). For ex-
ample, rs688551 minor allele frequency (MAF) =0.063,
odds ratio (OR) sCJD vs. control =0.92 (0.81–1.05),
rs319013 MAF =0.378 OR =0.94 (0.88–1.00) and
rs76547469 MAF = 0.061 OR = 0.96 (0.85–1.10). In our
sCJD study, assuming we genotyped perfectly, the func-
tional SNP has 80 % power at a MAF of 0.06 to detect an
additive heterozygous effect size of 1.19 [17].
Fig. 1 a There is no association signal at the PLCXD3 locus in 2500 sCJD cases compared to 10,548 controls. (b) There is only a modest
association signal at the PLCXD3 locus in 129 vCJD cases compared to 5020 UK controls.−Log10(P) values for genotyped and imputed SNPs are
plotted against their positions. PLCXD3 SNPs found to be significant in the GWAS by Bishop et al. are indicated in green and PLCXD3 SNPs
sequenced by Bishop et al. are in red. Schematic of PLCXD3 gene locus with exons represented in orange and intronic regions by the black line
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Table 1 PLCXD3 SNPs identified by GWAS and reported by Bishop et al. (†) and those subsequently resequenced by Bishop et al. (‡) are shown. P values are given for the
discovery and replication studies. SNP positions refer to GRCh37 build
SNP ID Position Genomic-control corrected
P-valueBishop et al. GWAS85
vCJD cases vs. 1481 controls
Allelic Fisher Exact P-valueBishop
et al. Resequencing120 vCJD cases
vs. publicly available controls
Allelic Fisher Exact P-valueBishop et
al. Resequencing109 sCJD cases vs.
publicly available controls
Frequentist additive P- valueMRC
Prion Unit GWAS129 vCJD cases
vs. 5020 UK controls
Frequentist additive P-valueMRC
Prion Unit GWAS2500 sCJD
cases vs. 10548 controls
rs3863150† 5:41506860 1.53 x 10−08 Not reported in study Not reported in study 0.000949 0.282
rs688551† 5:41506080 1.53 x 10−08 Not reported in study Not reported in study 0.000949 0.282
rs10075789† 5:41505703 1.53 x 10−08 Not reported in study Not reported in study 0.00105 0.282
rs676328† 5:41505689 1.53 x 10−08 Not reported in study Not reported in study 0.00115 0.257
rs545358‡ 5:41382691 Not reported in study <2.2 x 10−16 2.01 x 10−5 0.668 0.788
rs319013‡ 5:41382681 Not reported in study 1.25 x 10−06 4.69 x 10−8 0.331 0.139
rs76547469‡ 5:41382647 Not reported in study 0.247 0.0702 0.545 0.624
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With allele discrimination probes we confirmed geno-
types in 176 sCJD cases at both rs545358 (AA:AC:CC =
149:23:1) and at rs319013 (TT:TG:GG= 54:93:26) and in
119 vCJD cases at both rs545358 (AA:AC:CC = 102:17:0)
and at rs319013 (TT:TG:GG= 43:58:18). Genotypes for all
these cases were 100 % concordant with their imputed ge-
notypes when scored by the threshold method. Using
resequencing we further confirmed genotypes in 46 sCJD
cases at rs545358 (AA:AC:CC = 35:10:1) and at rs319013
(TT:TG:GG= 12:28:6) and in 47 vCJD cases at rs545358
(AA:AC:CC = 36:11:0) and at rs319013 (TT:TG:GG =
16:23:8). Again genotypes for all these cases were 100 %
concordant with their imputed genotypes in the GWAS.
Using whole exome sequencing in 376 CJD cases we
found only one non-synonymous heterozygous variant
in the PLCXD3 gene in a patient with sCJD
(exon2:c.C673G:p.L225V), however this variant was
also present in the 1000 Genomes control population
with a minor allele frequency of 0.0005. Additionally
we found a separate non-synonymous heterozygous
variant in PLCXD3 in one sample in the control popu-
lation which was not found in CJD cases. There was
no significant association of variants in PLCXD3 with
disease in the exome sequencing data (p = 0.566).
Discussion
We looked to replicate published findings at PLCXD3 in
the context of genomic studies of prion disease. We
show that there is no exceptional association of variants
in this gene with human prion disease. A critical step in
validating GWAS signals is replication of results and we
have been unable to do this in our much larger study of
CJD cases which inherently has more power to detect an
association [18]. A recent GWAS of 434 sCJD patients
and an independent replication cohort of 1109 sCJD pa-
tients was reported but apparently did not replicate a
strong signal at the PLCXD3 locus [19]. We suggest that
this gene should not be considered a priority candidate
for further study as a modifier in prion disease.
There are a number of reasons which together may
contribute towards the discrepancy between studies in-
cluding differences in sample-size and genotyping pro-
cedures. We also considered the possibility of errors in
genotyping or imputation in our study, and as a precau-
tion against this used a second method to confirm the
accuracy of our data.
We note some limitations of our own study. The sample
size for vCJD cases was necessarily small and we cannot
exclude the possibility of modest risk effects specific to
this human prion disease. In sCJD, we can exclude all but
very weak effects at the locus conferred by common SNPs,
and strong effects conferred by coding variation, but we
did not test for structural variation at PLCDX3, which was
reported genome-wide elsewhere [20]. We did not study
modifying effects of genetic variation on the clinical
phenotype of prion disease, which can be profound [21].
We did not do functional studies of PLCXD3, which in
our view are not warranted without substantial evidence
of genetic association.
Conclusion
Polymorphisms of PLCXD3 are unlikely to be risk factors
in human prion disease.
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